Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2015, Article ID 341042, 6 pages
http://dx.doi.org/10.1155/2015/341042
Research Article

Prognostic Value of MRS Metabolites in Postoperative Irradiated High Grade Gliomas

12nd Department of Radiology, Radiation Oncology Unit, Medical School, Attikon University Hospital, 1 Rimini Street, Haidari, 12462 Athens, Greece
2Encefalos Radiology Center, 3 Rizareiou & Chrisostomou Smirnis Street, Chalandri, 15233 Athens, Greece
3Medical Oncology Unit, 401 General Army Hospital, 10-12 Gennimata Street, Ampelokipi, 11524 Athens, Greece
4School of Health Sciences, Faculty of Medicine, Department of Radiotherapy, University of Thessaly, Biopolis, 41110 Larissa, Greece
51st Department of Radiology, Radiation Oncology Unit, Medical School, Aretaieion University Hospital, Vas Sofias 104 Avenue, 11521 Athens, Greece
6Radiotherapy Department, Alexandra Hospital, 11521 Athens, Greece
7Department of Radiation Oncology, AHEPA Hospital, Aristotle University of Thessaloniki, 1 Kyriakidi Street, 54636 Thessaloniki, Greece

Received 18 September 2014; Accepted 9 February 2015

Academic Editor: Ondrej Topolcan

Copyright © 2015 Maria Tolia et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Purpose. We studied the prognostic significance of Magnetic Resonance Spectroscopy (MRS) in operated high grade gliomas. Materials and Methods. Twelve patients were treated with radiotherapy and Temozolomide. The MRS data were taken four weeks after operation (before radiotherapy) and every six months after the completion of RT. The N-acetyl aspartate, choline, creatine, and myo-inositol parameters were quantified, analyzed, and correlated to recurrence-free survival (RFS). Results. The median RFS was 26.06 months. RFS was significantly worse in elderly patients along with the higher choline/creatine ratios at either baseline or six months post Radiotherapy . Median RFS was 23 months in high choline/creatine levels ≥2 at 6 months after radiotherapy and 11 months for those with <2 choline/creatine levels. There was a significant correlation of maximum difference of choline/creatine ratio with RFS (rho = 0.64, ). Conclusion. Age and choline/creatine ratio are strong independent prognostic factors in high grade gliomas.